[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"biomarker:cd19-gene":3},{"name":4,"total":5,"recruiting":6,"trials":7},"CD19 Gene",87,74,[8,16,23,30,36,42,49,55,61,67,73,79,85,91,97,103,109,115,121,127,133,139,145,151,157,163,169,175,181,187,193,198,204,210,215,221,227,232,238,244,250,257,263,269,275,281,287,292,298,304],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT06526793","Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed\u002FRefractory (R\u002FR) B-cell NHL",[12],"Phase 2","RECRUITING","2026-08-26T02:15:36.077529Z","2026-07-05T05:32:16.757959Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT06056102","CAR-T Cell Therapy for Desensitization in Kidney Transplantation",[20],"Phase 1","2026-08-26T02:18:26.932189Z","2026-07-05T05:32:16.746896Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":28,"content_modified":29},"NCT07081646","A Phase 1b\u002F2 Study of CAR T Cell Therapy Targeting CD19 and BCMA in Participants With Relapsed or Refractory AL Amyloidosis.",[27],"Phase 1\u002FPhase 2","2026-08-26T02:15:30.699880Z","2026-07-05T05:32:16.731350Z",{"nct_id":31,"title":32,"phases":33,"status":13,"updated_at":34,"content_modified":35},"NCT07015983","A Study of CC-97540 (BMS-986353 or Zola-cel), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite Immunosuppressants (Breakfree-SLE)",[12],"2026-08-03T00:59:52.468532Z","2026-07-05T05:32:16.725542Z",{"nct_id":37,"title":38,"phases":39,"status":13,"updated_at":40,"content_modified":41},"NCT07400029","A Study of Obecabtagene Autoleucel in People With B-cell Acute Lymphoblastic Leukemia",[12],"2026-08-26T02:17:17.791881Z","2026-07-05T05:32:16.679314Z",{"nct_id":43,"title":44,"phases":45,"status":13,"updated_at":47,"content_modified":48},"NCT07223021","A Study of Fludarabine Dosing in Children and Young Adults With B-cell Acute Lymphoblastic Leukemia",[46],"Phase 3","2026-08-26T02:16:47.762107Z","2026-07-05T05:32:16.665217Z",{"nct_id":50,"title":51,"phases":52,"status":13,"updated_at":53,"content_modified":54},"NCT07321652","Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL\u002FSLL",[46],"2026-08-26T02:19:14.560989Z","2026-06-17T02:29:30.059389Z",{"nct_id":56,"title":57,"phases":58,"status":13,"updated_at":59,"content_modified":60},"NCT07343934","huCART19-IL18-eDHFR Cells in Relapsed\u002FRefractory Follicular Lymphoma",[20],"2026-08-26T02:15:46.655893Z","2026-05-29T15:36:40.186042Z",{"nct_id":62,"title":63,"phases":64,"status":13,"updated_at":65,"content_modified":66},"NCT05786040","Tafasitamab and Rituximab for Front-Line Treatment of Post-Transplant Lymphoproliferative Disorder",[12],"2026-08-26T02:15:51.395565Z","2026-05-05T02:43:29.700475Z",{"nct_id":68,"title":69,"phases":70,"status":13,"updated_at":71,"content_modified":72},"NCT07133997","Recombinant Erwinia Asparaginase and Venetoclax in Combination With Blinatumomab for the Treatment of Relapsed or Refractory CD19 Positive B-cell Acute Lymphoblastic Leukemia",[20],"2026-08-26T02:17:20.511551Z","2026-05-05T02:43:29.580504Z",{"nct_id":74,"title":75,"phases":76,"status":13,"updated_at":77,"content_modified":78},"NCT07041099","A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Sjogren's Disease",[20],"2026-08-26T02:16:46.147215Z","2026-05-05T02:43:29.542856Z",{"nct_id":80,"title":81,"phases":82,"status":13,"updated_at":83,"content_modified":84},"NCT07096843","A Phase 2 Study of Budoprutug in Subjects With Primary Membranous Nephropathy",[12],"2026-08-26T02:18:21.216897Z","2026-05-05T02:43:29.465978Z",{"nct_id":86,"title":87,"phases":88,"status":13,"updated_at":89,"content_modified":90},"NCT07162038","Phase I Trial Integrating HLA-Haploidentical Anti-CD19 CAR-T Cells With Post-Transplantation Cyclophosphamide-Based HLA-Haploidentical Hematopoietic Cell Transplantation",[20],"2026-08-26T02:16:48.735701Z","2026-05-05T02:43:29.410020Z",{"nct_id":92,"title":93,"phases":94,"status":13,"updated_at":95,"content_modified":96},"NCT07053059","Phase 2 Study Assessing the Clinical Activity and Safety of Obecabtagene Autoleucel as a Consolidation in Patients With Newly Diagnosed High-risk B-cell Acute Lymphocytic Leukemia (ALL)",[12],"2026-08-26T02:18:19.586423Z","2026-05-05T02:43:29.369796Z",{"nct_id":98,"title":99,"phases":100,"status":13,"updated_at":101,"content_modified":102},"NCT05618925","Study for Subjects With Relapsed\u002FRefractory Non- Hodgkin Lymphoma",[20],"2026-08-26T02:16:02.918558Z","2026-05-05T02:43:29.222602Z",{"nct_id":104,"title":105,"phases":106,"status":13,"updated_at":107,"content_modified":108},"NCT07222579","Subcutaneous Blinatumomab for Treatment of Adult Patients With CD19-Positive Mixed Phenotype Acute Leukemia (MPAL)",[12],"2026-08-26T02:17:02.694423Z","2026-05-05T02:43:29.054327Z",{"nct_id":110,"title":111,"phases":112,"status":13,"updated_at":113,"content_modified":114},"NCT06408194","Autologous CD22 CAR T Cells Following Commercial CD19 CAR T Cells in B Cell Malignancies",[20],"2026-08-26T02:16:54.876240Z","2026-05-05T02:43:29.029325Z",{"nct_id":116,"title":117,"phases":118,"status":13,"updated_at":119,"content_modified":120},"NCT06137118","AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia",[27],"2026-08-26T02:16:42.787115Z","2026-05-05T02:43:29.024177Z",{"nct_id":122,"title":123,"phases":124,"status":13,"updated_at":125,"content_modified":126},"NCT04484012","Modified Immune Cells (CD19 CAR T Cells) and Acalabrutinib for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma",[12],"2026-08-26T02:18:59.761994Z","2026-05-05T02:43:28.843874Z",{"nct_id":128,"title":129,"phases":130,"status":13,"updated_at":131,"content_modified":132},"NCT06124157","A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)",[12],"2026-08-26T02:15:41.377360Z","2026-05-05T02:43:28.515234Z",{"nct_id":134,"title":135,"phases":136,"status":13,"updated_at":137,"content_modified":138},"NCT06559189","CD19x22 Chimeric Antigen Receptor T-cell Therapy (CAR T) in Pediatric B-ALL",[20],"2026-08-26T02:16:32.589113Z","2026-05-05T02:43:28.501492Z",{"nct_id":140,"title":141,"phases":142,"status":13,"updated_at":143,"content_modified":144},"NCT05010564","Trivalent CAR-T Cell in Acute B-Lineage Leukemia (TRICAR-ALL)",[20],"2026-08-26T02:15:53.461103Z","2026-05-05T02:43:28.287884Z",{"nct_id":146,"title":147,"phases":148,"status":13,"updated_at":149,"content_modified":150},"NCT04544592","UCD19 CarT in Treatment of Pediatric B-ALL and B-NHL",[27],"2026-08-26T02:18:15.214990Z","2026-05-05T02:43:28.281463Z",{"nct_id":152,"title":153,"phases":154,"status":13,"updated_at":155,"content_modified":156},"NCT06317662","Testing the Addition of the Anti-cancer Drug Venetoclax and\u002For the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia",[12],"2026-08-26T02:17:58.890423Z","2026-05-05T02:43:27.976183Z",{"nct_id":158,"title":159,"phases":160,"status":13,"updated_at":161,"content_modified":162},"NCT05910801","Tafasitamab, Lenalidomide and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma",[12],"2026-08-26T02:15:23.202838Z","2026-05-05T02:43:27.931684Z",{"nct_id":164,"title":165,"phases":166,"status":13,"updated_at":167,"content_modified":168},"NCT06144606","Study of KTE-X19 in Minimal Residual Disease (MRD) Positive B-Cell Acute Lymphoblastic Leukemia (B-ALL)",[12],"2026-08-26T02:16:44.178623Z","2026-05-05T02:43:27.927667Z",{"nct_id":170,"title":171,"phases":172,"status":13,"updated_at":173,"content_modified":174},"NCT06287229","Phase Ib\u002FII Study Assessing the Clinical Activity and Safety of Brexucabtagene Autoleucel as a Consolidation in Patients With Relapsed\u002FRefractory (R\u002FR) and Newly Diagnosed B-cell Acute Lymphocytic Leukemia (ALL) Post Cytoreduction With Mini-HCVD-inotuzumab-blinatumomab\u002FHCVAD-inotuzumab-blinatumomab",[27],"2026-08-26T02:16:26.411851Z","2026-05-05T02:43:27.836826Z",{"nct_id":176,"title":177,"phases":178,"status":13,"updated_at":179,"content_modified":180},"NCT07257419","CD45RA-depleted CD19-CAR T Cell Consolidation After TCRαβ+\u002FCD19 B Cell-depleted Haploidentical Hematopoietic Cell Transplantation for Relapsed\u002FRefractory CD19+ ALL and Lymphoma",[20],"2026-08-26T02:19:23.493898Z","2026-05-05T02:43:27.676036Z",{"nct_id":182,"title":183,"phases":184,"status":13,"updated_at":185,"content_modified":186},"NCT05674175","Co-administration of CART22-65s and huCART19 for B-ALL",[27],"2026-08-26T02:15:56.561131Z","2026-05-05T02:43:27.600390Z",{"nct_id":188,"title":189,"phases":190,"status":13,"updated_at":191,"content_modified":192},"NCT05794958","Evaluate Safety of Axicabtagene Ciloleucel Reinfusion (Axi-Cel-2) in Patients With Relapsed and\u002For Refractory Second Line High-Risk Non-Hodgkin Lymphoma After Standard of Care Axi-Cel",[20],"2026-08-26T02:19:25.538428Z","2026-05-05T02:43:27.503923Z",{"nct_id":194,"title":195,"phases":196,"status":13,"updated_at":40,"content_modified":197},"NCT06847269","CAR T CELL Therapy for Pediatric, Adolescent and Young Adult Patients With CD19-Positive Leukemia",[12],"2026-05-05T02:43:27.418413Z",{"nct_id":199,"title":200,"phases":201,"status":13,"updated_at":202,"content_modified":203},"NCT05645718","Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic Leukemia",[12],"2026-08-26T02:17:22.153941Z","2026-05-05T02:43:27.390966Z",{"nct_id":205,"title":206,"phases":207,"status":13,"updated_at":208,"content_modified":209},"NCT06613360","A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Systemic Lupus Erythematosus",[20],"2026-08-26T02:18:03.638950Z","2026-05-05T02:43:27.314554Z",{"nct_id":211,"title":212,"phases":213,"status":13,"updated_at":167,"content_modified":214},"NCT05801913","Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) for the Treatment of Intermediate or High Grade B-Cell Non-Hodgkin Lymphoma",[20],"2026-05-05T02:43:27.275760Z",{"nct_id":216,"title":217,"phases":218,"status":13,"updated_at":219,"content_modified":220},"NCT06138132","A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell ( CAR-T) Therapy in Subjects With Non-relapsing and Progressive Forms of Multiple Sclerosis",[20],"2026-08-26T02:16:29.226604Z","2026-05-05T02:43:27.264594Z",{"nct_id":222,"title":223,"phases":224,"status":13,"updated_at":225,"content_modified":226},"NCT05625594","Intracerebroventricular Administration of CD19-CAR T Cells (CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn\u002FMem T-lymphocytes) for the Treatment of Central Nervous System Lymphoma",[20],"2026-08-26T02:18:43.501109Z","2026-05-05T02:43:27.177772Z",{"nct_id":228,"title":229,"phases":230,"status":13,"updated_at":155,"content_modified":231},"NCT06777979","CD19-CD22-Bispecific Chimeric Antigen Receptor (CAR) T Cell Therapy for Pediatric Patients With Acute Lymphoblastic Leukemia",[20],"2026-05-05T02:43:26.924544Z",{"nct_id":233,"title":234,"phases":235,"status":13,"updated_at":236,"content_modified":237},"NCT05052528","Fludarabine and Cyclophosphamide With or Without Rituximab Before CD19 Chimeric Antigen Receptor T Cells for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma",[20],"2026-08-26T02:18:52.966503Z","2026-05-05T02:35:31.778323Z",{"nct_id":239,"title":240,"phases":241,"status":13,"updated_at":242,"content_modified":243},"NCT06287528","A Study of 19-28z\u002FIL-18 in People With Acute Lymphoblastic Leukemia (ALL)",[20],"2026-08-26T02:18:49.989941Z","2026-05-05T02:35:31.697561Z",{"nct_id":245,"title":246,"phases":247,"status":13,"updated_at":248,"content_modified":249},"NCT04276870","Orphan Indications for CD19 Redirected Autologous T Cells",[12],"2026-08-26T02:15:44.309045Z","2026-05-05T02:35:31.686030Z",{"nct_id":251,"title":252,"phases":253,"status":13,"updated_at":255,"content_modified":256},"NCT06735690","Allogeneic CMV-Specific CD19-CAR T Cells Plus CMV-MVA Triplex Vaccine After Matched Related Donor Hematopoietic Cell Transplant for the Treatment of Patients With High-Risk Acute Lymphoblastic Leukemia",[254],"Early Phase 1","2026-08-26T02:16:04.914942Z","2026-05-05T02:35:31.635862Z",{"nct_id":258,"title":259,"phases":260,"status":13,"updated_at":261,"content_modified":262},"NCT06213311","A Study of Axicabtagene Ciloleucel and Glofitamab as Second-Line Therapy for Relapsed or Refractory Patients With Large B Cell Lymphoma",[12],"2026-08-26T02:17:01.714035Z","2026-04-29T02:57:57.157278Z",{"nct_id":264,"title":265,"phases":266,"status":13,"updated_at":267,"content_modified":268},"NCT05365659","IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas",[20],"2026-08-26T02:18:09.641312Z","2026-07-30T01:46:14.462340Z",{"nct_id":270,"title":271,"phases":272,"status":13,"updated_at":273,"content_modified":274},"NCT06364423","Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Leukemias",[27],"2026-08-26T02:18:24.494016Z","2026-07-05T05:32:16.752213Z",{"nct_id":276,"title":277,"phases":278,"status":13,"updated_at":279,"content_modified":280},"NCT06557265","A Phase 1\u002F2 Study of NKX019 in Subjects With Autoimmune Disease (Ntrust-1)",[27],"2026-08-26T02:18:58.958025Z","2026-06-17T02:29:30.003977Z",{"nct_id":282,"title":283,"phases":284,"status":13,"updated_at":285,"content_modified":286},"NCT05848687","TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II",[27],"2026-08-26T02:16:24.970704Z","2026-05-05T02:43:29.336397Z",{"nct_id":288,"title":289,"phases":290,"status":13,"updated_at":137,"content_modified":291},"NCT03595917","ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML",[20],"2026-05-05T02:43:29.224482Z",{"nct_id":293,"title":294,"phases":295,"status":13,"updated_at":296,"content_modified":297},"NCT07295847","A Study of AZD0120 in Autoimmune Diseases",[20],"2026-08-26T02:15:57.572488Z","2026-05-05T02:43:28.813958Z",{"nct_id":299,"title":300,"phases":301,"status":13,"updated_at":302,"content_modified":303},"NCT01853631","Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)",[20],"2026-08-26T02:19:30.857183Z","2026-05-05T02:43:28.649787Z",{"nct_id":305,"title":306,"phases":307,"status":13,"updated_at":308,"content_modified":309},"NCT05702853","Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed\u002FRefractory NHL, CLL\u002FSLL",[27],"2026-08-26T02:16:18.872924Z","2026-05-05T02:43:28.285448Z"]